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ABSTRACT 
Linked pharmacometric and pharmacoeconomic models provide a structured approach for 
assessing the value of candidate drugs in development. The aim of this study was to assess 
the utility of such an approach for identifying the properties of xanthine oxidase inhibitors 
(XOi) providing improved forgiveness to non-adherence and estimate the maximum 
reimbursement price. The pharmacometric and pharmacoeconomic models were used to 
simulate the time course of serum uric acid concentrations, and estimate quality-adjusted life 
years and costs for the XOi febuxostat and a range of hypothetical analogues. Compounds 
with reduced clearance or increased potency were more forgiving to missed doses, however, 
even following relatively large changes in these properties the predicted maximum 
reimbursement prices represented an increase of only 19% above febuxostat 80 mg. Linked 
pharmacometric and pharmacoeconomic modelling methods have the potential to inform 
early drug development by providing an indication of pricing options that may permit 
reimbursement. 
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INTRODUCTION 
Linked pharmacokinetic-pharmacodynamic-pharmacoeconomic (PKPDPE) models can 
provide a framework capable of testing the influence of drug pharmacology on long term 
clinical and economic outcomes, such as cost-effectiveness and value based pricing.1–4 This 
offers distinct advantages over conventional pharmacoeconomic analyses during clinical 
drug development by making explicit consideration of the relation between dose taking, 
dose-response, health outcomes and costs. Linked PKPDPE modelling can be used to 
predict the likelihood of therapeutic success and quantify the implications for pricing. One 
application, which exploits the mechanistic properties of this approach, is in determining the 
influence of non-adherence on the value of treatments. This represents a natural extension 
to previous research in which different patterns of adherence serve as inputs to PK5,6 and 
PKPD7–9 models, and provides a basis for estimating cost-effectiveness in preference to 
cost-efficacy.10 
Imperfect medication adherence can limit the benefit of treatments, result in poorer 
outcomes for patients, and increase healthcare costs.11 Medication adherence can be 
decomposed into three distinct phases; 1) the initiation of treatment, 2) the degree to which a 
patient’s dose taking matches the prescribed regimen while nominally adhering 
(implementation) and 3) the discontinuation of treatment (persistence).12 The design of 
medicines which remain effective when dose implementation is erratic – a property known as 
‘forgiveness’13,14 – may improve treatment effectiveness under conditions of routine care and 
provide added value. Conventional PK and PD modelling can offer insights on the impact of 
variable dosing on clinical endpoints15,16; however to our knowledge, there are no published 
methods for predicting the value of improving treatment forgiveness.  
Despite the availability of effective urate-lowering therapies (ULTs) for gout, such as 
xanthine oxidase inhibitors (XOi) allopurinol and febuxostat, many patients fail to achieve 
serum uric acid target concentrations. Within clinical trials, allopurinol 300 mg/day reduced 
serum uric acid (sUA) concentrations to below target (6 mg/dL) in 12% – 41% of patients17–
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21; and febuxostat 80mg/day in 57% – 76% of patients17–19. Rates of target attainment in 
routine practice are also low, and range from 22% (US primary care or rheumatology 
clinic)22, 38% (UK primary care)23 to 45% (UK rheumatology)24. A principal cause of 
treatment failure is non-adherence, with as few as 40% of patients being classed as 
adherent (medication possession ratio > 0.8) using prescription claims data but with higher 
estimates obtained using other methods.25,26 
One potential way in which the next generation XOi could add value is through improved 
forgiveness. Of the many structurally dissimilar candidate lead compounds27, the potential 
for one to have such a property e.g. through reduced clearance or increased potency, could 
result in improved use-effectiveness.28 More forgiving drugs that retain greater effectiveness 
under real world adherence would be expected to result in quality of life benefits, and 
potentially impact on costs, compared with existing treatments. Many jurisdictions operate a 
form of value-based pricing where the maximum reimbursement price is linked to the added 
value of a medicine, in terms of both cost and health impacts. A higher maximum 
reimbursement price makes it more likely that a pharmaceutical company would achieve a 
return on investment.  
This study uses real-world adherence data and PKPDPE modelling to simulate the 
effectiveness and determine the value of a series of hypothetical XOi. The aim was to 
assess the utility of using a PKPDPE model to link pharmacology to treatment effectiveness 
to the maximum reimbursement price in order to inform early decision making based on the 
predicted value that could be gained from developing a more forgiving drug.  
RESULTS 
The time courses of drug concentration in plasma and sUA concentration following single 
doses are presented in Figure 1 to illustrate the differences in pharmacokinetics and 
pharmacodynamics between febuxostat and hypothetical ULTs. The doses of hypothetical 
ULTs of group B (reduced IC50 and dose) and C (lower clearance and dose reduction) are 
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reduced and consequently plasma concentrations of B4 and C4 are lower than febuxostat at 
80 mg and 120 mg. A4 (reduced IC50) results in the greatest reduction in sUA concentration 
but its effect is transient relative to C4 with an extended elimination half-life. 
The predicted response rates for the hypothetical cohort over all PKPD model simulations 
are summarised in Table 1, where several possible measures of response have been 
presented. Febuxostat 80 mg and 120 mg were predicted to result in 55% and 64% of 
subjects with a mean sUA concentration below a 6 mg/dL target respectively. The 
hypothetical ULTs leading to the greatest proportion of responders was C4 (extended half-
life with dose reduction) and A4 (increased potency without dose reduction) both achieving < 
6 mg/dL in 75% of subjects. Scenarios assuming a greater potency and a reduced dose 
resulted in slightly lower response rates, down to 51%, relative to febuxostat 80 mg. 
Average response rates (< 6 mg/dL) over all PKPD simulations by dose implementation 
groups, as shown in Table S1, are presented in Figure 2. There is very little differentiation 
between the ULTs when implementation is below 20% or above 90%, with the best-worst 
treatment differences being between 0.8 and 10.3 percentage points. Greater differentiation 
occurs between 20% and 90%, where the best-worst treatment difference ranges from 15.1 
to 38.8 percentage points. A more pronounced pattern is observed for sustained treatment 
response, Figure S1, where there is no response predicted until at least 40% dose 
implementation. Only once implementation exceeds 70% of doses taken are high response 
rates (> 50%) achieved.   
Table 2 presents the estimated maximum reimbursement prices at which treatments are cost 
effective, based on differences in estimated lifetime QALYs and costs, resulting from 
expected changes in flare frequency. Prices are given using either febuxostat 80 mg or 120 
mg as the comparator. The highest maximum reimbursement prices are achieved by A4 and 
C4, which are expected to be cost effective at an annual price of £376, an increase of 19% 
on febuxostat 80 mg at a threshold of £20,000 per QALY. 
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Figure 3 shows the relationship between the responder rate and the pricing of a hypothetical 
ULT versus the comparator febuxostat 80 mg. The price axis is the difference between the 
maximum reimbursement prices at every response rate compared with the price of 
febuxostat 80 mg, hence the price at the response rate of 55% is fixed at £0. The two curves 
plot the relationship for a £20,000 per QALY cost effectiveness threshold and a probability of 
10% and 50% of being cost effective at or below this threshold. This curve provides an 
estimate of the maximum reimbursement price for any response rate, and indicates that with 
100% responder rate the maximum reimbursement price would be £140 above the annual 
cost of febuxostat 80 mg. 
DISCUSSION 
This study has demonstrated the application of linked PKPDPE models to inform drug 
development by estimating the maximum reimbursement price from drug pharmacology, 
using real-world data on medication adherence. In this case study, hypothetical XOi with 
reduced dose and extended duration of action were predicted to increase the proportion of 
treatment responders to a similar extent as those with increased potency alone. Simulations 
estimated a proportion of patients responding to treatment for these more ‘forgiving’ ULTs of 
between 60% and 75% compared with 55% for febuxostat 80 mg. Based on this 
improvement and assuming that treatment benefit is limited to a reduction in the frequency of 
acute gout flares, maximum reimbursement prices were estimated of between 4% and 19% 
above the £317.72 current annual cost of febuxostat using a cost effectiveness threshold of 
£20,000 per QALY gained. 
The results of this study suggest that, under conditions of imperfect adherence, reduced 
clearance is of equal value as a target for early candidate selection as increased potency. 
The identification of compounds with long elimination half-lives, while maintaining 
bioavailability and potency may be challenging.  However, some structurally diverse and 
highly potent XOi molecules have been identified and these may offer some potential lead 
candidates27, so further research and drug discovery endeavours could be justified. While 
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there are alterative ULT mechanisms, such as uricosurics which lower sUA by stimulating its 
renal excretion, these have had limited success due to safety concerns.29 Similarly, 
administration of the enzyme uricase (e.g. pegloticase) that converts uric acid into the more 
soluble component, allantoin, is not widely used due to occurrence of anti-drug antibodies, 
injection site reactions and its high cost.30 
The linkage of pharmacometrics with pharmacoeconomics remains relatively novel and there 
are few published examples, but has potential across a range of applications from early drug 
research and development2; in estimating cost effectiveness in alternative subgroups and 
treatment protocols31; in the evaluation of complex pharmaceutical interventions such as 
pharmacogenetic testing32; and modelling health economics of treatments for use during 
pandemics 33. Pharmacometrics has been used to study issues relating to medication 
adherence for some time (for example Vrijens et al. 200534). This study is the first, of which 
we are aware, to combine adherence, pharmacometrics and pharmacoeconomics to inform 
early drug design decisions. In doing so this further demonstrates the value of an 
interdisciplinary approach and the need to interconnect existing methods to improve 
efficiency in drug development. As such, linked PKPDPE modelling may be seen as an 
additional component within the model informed drug development paradigm.35 
This study has advantages over conventional pharmacometric studies that do not assess the 
future value of compounds beyond market authorisation; and conversely, it has advantages 
over standard pharmacoeconomic practices which do not account for exposure response 
relationships. It has benefitted from a semi-mechanistic pharmacodynamic model that can 
account for the system dynamics resulting from intermittent dose taking. Unlike in some 
previous economic evaluations of ULTs36–38, in this study, the clinical benefits of lowering 
sUA concentration have been assumed to be limited to reduced frequency of flares alone. 
However, this is consistent with the findings of recent meta-analyses.39 
Limitations of this study include the assumptions which were necessary in order to develop a 
model structure and to obtain parameters estimates. It has been assumed that the structure 
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of the pharmacometric and pharmacoeconomic models provide a sufficiently accurate 
representation of ULTs and their impacts to make predictions. The PKPD model was 
developed from a variety of published sources without fully accounting for the additional 
uncertainty this introduced. Aspects of the pharmacoeconomic modelling, such as the 
frequency of acute gout flares, relied on survey data obtained from a small number of 
patients. We have not considered the safety aspects of hypothetical XOi which would inform 
dose selection, and would need to be accounted for in pharmacoeconomic models in terms 
of the cost and health implications. The adherence data was not collected in gout patients 
but does contain a wide variety of adherence patterns and the overall low level of adherence 
is consistent with studies on the routine use of ULTs. 
Many jurisdictions make use of economic evaluations as a part of the decision making 
process of whether to reimburse medicines having obtained marketing authorisation. A new 
medicine failing to meet the criteria for cost effectiveness may not be marketable at a 
commercially viable price or gain sufficient market penetration for adequate return on 
investment. The framework used here provides a direct link between pharmacology and the 
probability of a medicine being cost-effective. These methods have the potential to inform 
early drug development by providing an indication of whether drug candidates possess the 
properties that would result in a maximum reimbursement price that justifies their 
progression through the long and costly drug development process.  
METHODS 
Overview 
In the first stage, the time course of sUA was simulated based on real-world dose taking 
histories and using a range of drug models, representing both real-world and hypothetical 
XOi. This stage was repeated a large number of times with resampling from probability 
distributions for patient characteristics, including baseline sUA concentration, age and 
weight. In the second stage the post-treatment sUA was used to predict the annual 
9 
 
frequency of acute gout flares over the patients’ remaining lifetime and to estimate the 
overall costs and impacts on quality-adjusted life years. 
Pharmacometric and Pharmacoeconomic Models 
An existing two compartment pharmacokinetic (PK) model and multi-compartment semi-
mechanistic pharmacodynamic (PD) model developed for febuxostat7 was used to simulate 
sUA concentrations. The structure of the pharmacodynamics model has been reproduced in 
Figure 4, while PK and PD model parameters are provided in the Supplementary Material. In 
addition to febuxostat at approved daily doses of 80 mg and 120 mg40, twelve ‘hypothetical’ 
ULTs were assessed by changing the values of potency or clearance parameters for 
febuxostat (Table 3).  
The rationale for the clearance, potency and dose adjustments is that i) reduced clearance 
prolongs residual drug concentration (and therefore extends the duration of action), but for 
an unbiased comparison a dose reduction was made to maintain the same drug exposure 
(area under the concentration curve); and ii) for a given concentration, a more potent drug 
will result in greater effect and we have, therefore, tested scenarios with and without dose 
adjustments. In reality, decisions concerning dose would be guided by a consideration both 
of the efficacy and the safety profiles of a candidate compound. We have not considered 
safety in this study.   
The pharmacoeconomic model used a Markov state-transition structure with a 3-month time 
cycle to estimate costs and QALYs in a cohort of patients eligible for ULT. An overview of 
the model structure is given in Figure S2, model parameters are provided in the 
Supplementary Material and a comprehensive description of the model can be found 
elsewhere.1 The approach to modelling cost effectiveness is consistent with the methods of 
the National Institute for Health and Care Excellence in the UK41, adopting the cost 
perspective of the National Health Service in the UK, a lifetime (50 year) time horizon, and 
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costs and QALYs both discounted at a rate of 3.5% per annum.42 The model was 
implemented in R version 3.5.1.43 
For each ULT in Table 3, a nominal 10,000 patients are initially allocated to treatment and 
distributed between four sUA sub-states (<6, 6 to <8, 8 to <10 and ≥10 mg/dL) based on the 
results of PKPD simulations. In each model cycle, a proportion of patients discontinue 
treatment and are redistributed between the sUA sub-states to an untreated sUA distribution. 
A proportion also move to a dead state according to all-cause mortality probabilities derived 
from life tables for England and Wales in 2015.44 The model conservatively assumes that the 
only benefit of reducing sUA concentrations is to reduce the frequency of acute gout flares. 
A flare frequency distribution was derived from cross-sectional survey data45 across five 
categories; 0, 1-2, 3, 4-5 and 6+ flares per annum. Fewer gout flares then result in improved 
quality of life and reduced treatment costs.45  
Adherence Data  
Adherence to ULTs was assumed from real world data on chronic treatment (119 subjects, 
15,959 individual doses and follow-up between 90 and 529 days46,47) using electronically-
recorded pill bottle cap opening times48 (MEMS, Aardex Group). Many of the adherence 
patterns are characterised by an implementation phase of varying levels of adherence 
followed by a complete cessation of doses prior to the end of the observation period. 
Instances of non-adherence following the implementation phase were discarded, as 
discontinuation was modelled separately in the pharmacoeconomic model. The distribution 
of dose implementation is given in Table S1, while figures showing all doses taken by every 
subject are provided in Figures S3-S7 in the Supplementary Material. 
Simulation Modelling 
Linked PKPDPE simulations were performed for each of the 14 ULTs. The pharmacometric 
stage was performed for each of the 119 real world adherence patterns ranging from 57 
days to 529 days of dose implementation. Each simulation was repeated 500 times with 
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resampling from individual random effects and from the probability distributions (based on 
clinical trial baseline data19) assumed for subject covariates including age (log-normal), 
weight (log-normal) and baseline sUA concentration (normal). However, uncertainty in the 
parameter estimates, in the estimates of the random effects parameters and residual 
variability was not included in PKPD simulations.  
The simulated sUA time courses were used to generate post-treatment sUA concentration 
distributions across four states for use in the pharmacoeconomic model. These were 
obtained by taking the mean of the simulated daily sUA levels for days beyond day 50 but 
before discontinuation. The primary measure of treatment response for a ULT, equivalent to 
the primary outcome measure used in many clinical trials17–19, is the proportion of subject 
simulations in the < 6 mg/dL state. Further alternative measures of treatment response were 
derived using daily sUA concentrations for all available days beyond day 50 but before 
discontinuation. The proportions of subject simulations which were < 6 mg/dL for at least 80, 
70, or 60% of days have been calculated to measure sustained response. Although not 
reported in clinical trials, there are more likely to be associated with a reduction in gout 
symptoms49. 
In each iteration of the pharmacoeconomic model, the process of collapsing sUA 
concentration measurements on to the four sUA states was repeated with random sampling 
to bootstrap and propagate PKPD variability. Other pharmacoeconomic model inputs, such 
as flare frequency distributions, health state utilities and discontinuation rates, were also 
varied according to probability distributions used to represent uncertainty regarding their true 
value. Further details of the model parameters and probability distributions are summarised 
in the Supplementary Material. A total of 5,000 pharmacoeconomic models were performed 
for each unique ULT and adherence pattern combination. 
The outputs of the pharmacoeconomic model for each ULT are the mean per patient lifetime 
QALYs and costs associated with gout following the initiation of treatment and the mean 
number of cycles of drug supplied. All hypothetical ULTs were compared with febuxostat 80 
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mg or 120 mg, both with an annual price of £317.72.40 Cost effectiveness thresholds were 
used to determine whether a higher cost treatment is sufficiently effective to justify 
reimbursement. We have used a cost effectiveness threshold of £20,000 per QALY gained 
which is routinely used in the UK.50  
Where a hypothetical ULT is more effective than febuxostat 80 mg we have estimated the 
maximum price at which the hypothetical ULT would be cost effective using the mean QALY 
and cost differences. The maximum cost effective price can be found by solving equation 1 
for 𝑃ℎ when net monetary benefit (NMB) is equal to zero.  
𝑁𝑀𝐵 =  𝜆 Δ𝑄 −  (Δ𝐶𝑁𝐷 + (𝑆ℎ ∗ 𝑃ℎ −  𝑆𝑓 ∗ 𝑃𝑓))    (1) 
NMB is the net monetary benefit, 𝜆 is the cost effectiveness threshold, Δ𝑄 is the difference in 
lifetime QALYs, Δ𝐶𝑁𝐷 is the difference in non-drug costs, 𝑆𝑓 is the number of cycles 
febuxostat 80/120 mg, 𝑃𝑓is the price of febuxostat 80/120 mg, 𝑆ℎis the number of cycles of 
hypothetical ULT, and 𝑃ℎ is the price of the hypothetical ULT.  
 
ACKNOWLEDGEMENTS 
We acknowledge the support of the Supercomputing Wales project, which is part-funded by 
the European Union's Convergence European Regional Development Fund, administered by 
the Welsh Government. 
AUTHOR CONTRIBUTIONS 
D.H.-M., E.S., S.M., and D.A.H. wrote the manuscript; D.H.-M. and D.A.H. designed the 
research; D.H.-M. performed the research; D.H.-M. analyzed the data. 
 
 
13 
 
STUDY HIGHLIGHTS 
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? 
Linked pharmacometric and pharmacoeconomic modelling has been shown to have 
potential utility across a range of different applications.  
WHAT QUESTION DID THIS STUDY ADDRESS? 
This study has sought to extend linked pharmacometric and pharmacoeconomic models to 
account for realistic drug adherence and quantify the value of drugs with improved 
forgiveness to missed doses. 
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE? 
This was a case study of the application of linked pharmacometric and pharmacoeconomic 
models to quantify the value of hypothetical xanthine oxidase inhibitors for treating gout, 
based on their pharmacology. The maximum reimbursement price for hypothetical agents 
with increased potency or reduced clearance was estimated based on treatment success 
rates. This novel framework provides a direct link between drug pharmacology and the 
probability of a drug being cost-effective while explicitly accounting for realistic medication 
adherence. 
HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY AND THERAPEUTICS? 
These methods have the potential to inform early drug development by providing an 
indication of whether drug candidates possess the properties that would result in a maximum 
reimbursement price that justifies their progression through the long and costly drug 
development process. 
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Figure 1. Simulated drug plasma concentration and serum uric acid time course following a 
single oral dose (taken at hour 12) of febuxostat 80mg or 120mg as well as 3 hypothetical 
ULTs (simulations used a reference subject of age 60, weight 100 kg, and baseline sUA of 9 
mg/dL) 
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Figure 2. Mean treatment response rates for hypothetical ULTs compared with febuxostat 
80mg by dose implementation using response defined using mean daily sUA concentration 
below 6 mg/dL target 
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Figure 3. Curve of estimated pricing to achieve cost effectiveness versus febuxostat 80 mg 
with probability of 50% and 10% at a willingness to pay threshold of £20,000 
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Figure 4. Diagrammatic and mathematical representations of the pharmacodynamics of 
dual-urate lowering therapies. k0, k1, k2 and k3 are the rate parameters for the production of 
xanthine, xanthine to uric acid conversion, removal of xanthine to urine and removal of uric 
acid to urine, respectively. INH1, INH2, and STIM1 are the pharmacodynamic model drug 
functions. AX and AUA are the total time-varying amounts of xanthine and uric acid in serum, 
respectively. AuX and AuUA are total amounts of xanthine and uric acid removed to urine, 
respectively. C1(t) and C2(t) are the plasma concentrations of drug in the central and 
peripheral pharmacokinetic compartments respectively. 
